Fortress Biotech, Inc. (NASDAQ:FBIOP – Get Free Report) was down 2.1% on Monday . The stock traded as low as $5.05 and last traded at $5.08. Approximately 25,885 shares were traded during trading, an increase of 50% from the average daily volume of 17,223 shares. The stock had previously closed at $5.19.
Fortress Biotech Stock Down 2.1 %
The business has a 50 day simple moving average of $6.06 and a 200-day simple moving average of $6.08.
About Fortress Biotech
Fortress Biotech, Inc, a biopharmaceutical company, develops dermatology, pharmaceutical, and biotechnology products in the United States. The company markets dermatology products, such as Qbrexza a medicated cloth towelette for the treatment of primary axillary hyperhidrosis; Accutane capsules for severe recalcitrant nodular acne; Amzeeq for severe acne vulgaris; Zilxi, a topical foam; Exelderm cream and solution for topical use; Targadox an oral doxycycline drug for adjunctive therapy for severe acne; Luxamend; sulconazole nitrate cream and solution for tinea cruris and tinea corporis; and doxycycline hyclate tablet.
Recommended Stories
- Five stocks we like better than Fortress Biotech
- What is a Low P/E Ratio and What Does it Tell Investors?
- Why NVIDIA Stock Could Soar Despite Wall Street Downgrades
- How Technical Indicators Can Help You Find Oversold Stocks
- Top 3 Large Cap Stocks Insiders Bought in Q1: Buy, Sell, or Hold
- What Are the U.K. Market Holidays? How to Invest and Trade
- 3 Hot New IPOs Defying the 2025 Market Slump
Receive News & Ratings for Fortress Biotech Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Fortress Biotech and related companies with MarketBeat.com's FREE daily email newsletter.
